A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 22
- 试验地点
- 13
- 主要终点
- Safety and tolerability of PRT3645: AEs, CTCAE Assessments
研究概览
简要总结
This is a Phase 1 dose-escalation study of PRT3645, a Cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor, in patients with advanced or metastatic solid tumors. The purpose of this study is to investigate the safety, tolerability, dose limiting toxicity, and to determine maximally tolerated dose and recommended phase 2 dose to be used in subsequent development of PRT3645.
详细描述
This is an open-label, multicenter, dose-escalation Phase 1 study of PRT3645, a CDK4/6 inhibitor, evaluating patients with selected advanced or metastatic solid tumors including breast cancer (BC), glioblastoma (GBM), non-small cell lung cancer (NSCLC), sarcomas, head and neck squamous cell carcinoma (HNSCC), malignant mesothelioma, and endometrial cancer. The study plan expects to evaluate approximately eight dose levels however additional dose levels may be explored. Taking into account pharmacokinetic and pharmacodynamic data from the preceding dose levels, the dose may be escalated until a dose limiting toxicity is identified. Up to 15 patients may be enrolled at a dose shown to be tolerated for confirmation of the MTD and/or RP2D.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed advanced, recurrent, or metastatic solid tumor malignancy that have either progress or ineligible for standard of care therapy:
- •HR+ and HER2- or HR+ and HER2+ breast cancer
- •Recurrent GBM (IDH wild type) or CDKN2A/B homozygous deleted IDH-mutant astrocytoma
- •KRAS-mutant or SMARCA4 loss NSCLC
- •CDK pathway alternation in any of the following tumor types: malignant mesothelioma, HPV-negative HNSCC (including oral cavity, oropharynx, hypopharynx, and larynx), sarcoma, or NSCLC
- •Estrogen receptor positive with TP53 wild type endometrial cancer
- •Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures
- •Must have measurable or non-measureable (but evaluable) disease
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 or Karnofsky Performance Status (KPS) ≥80% (KPS is for GBM only)
- •Adequate organ function.
- •Able to swallow and retain oral medication.
- •Must provide either archival or fresh tumor tissue sample during screening.
排除标准
- •Participants with advanced, symptomatic, extensive visceral disease.
- •Active inflammatory bowel disease or chronic diarrhea, short bowel syndrome, any upper gastrointestinal surgery including gastric resection, known malabsorption syndrome, or other condition that may impair absorption of PRT
- •Treatment with strong inhibitors of CYP3A
- •History of another malignancy within 3 years except for adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive or indolent malignancies, or malignancies previously treated with curative intent and not on active therapy or expected to require treatment or recurrence during the study.
- •Clinically significant or uncontrolled cardiac disease, uncontrolled electrolyte disorders, uncontrolled or symptomatic CNS metastases or leptomeningeal disease except for GBM.
- •Endometrial cancer patients who had received prior treatment with a CDK 4/6 inhibitor.
研究组 & 干预措施
PRT3645
PRT3645 capsules will be self-administered once daily, continuously, at the dose-level assigned
干预措施: PRT3645 (Drug)
结局指标
主要结局
Safety and tolerability of PRT3645: AEs, CTCAE Assessments
时间窗: Baseline through approximately 2 years
Safety and tolerability will be evaluated by incidence of DLTs, laboratory measurements, severity of adverse events (AEs) according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0.
Maximally tolerated dose (MTD)/Recommended phase 2 dose (RP2D) of PRT3645
时间窗: Baseline through approximately 2 years
The MTD/RP2D will be established for further investigation in participants with advanced solid tumors
Dose limiting toxicity (DLT) of PRT3645
时间窗: Baseline through Day 28
Dose limiting toxicity will be evaluated over the 28-day observation period
次要结局
- Efficacy of PRT3645: Tumor assessment and responses(Baseline through approximately 2 years)
- Pharmacokinetic profile of PRT3645: Minimum and maximum observed plasma concentration(Baseline through approximately 2 years)
- Pharmacodynamic effect of PRT3645: Target engagement(Baseline through approximately 2 years)